Back to Search
Start Over
Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma
- Source :
- Leukemia & Lymphoma. 55:2514-2519
- Publication Year :
- 2014
- Publisher :
- Informa UK Limited, 2014.
-
Abstract
- We retrospectively evaluated the safety and efficacy of high-dose chemotherapy consisting of cyclophosphamide, etoposide and ranimustine (CEM) with autologous peripheral blood stem cell transplant (PBSCT) in 55 adult patients with relapsed or high-risk de novo diffuse large B-cell lymphoma (DLBCL) or DLBCL associated with follicular lymphoma. This included 36 patients in the upfront setting in their first complete remission. The median follow-up of 42 patients surviving at the time of the analysis was 52 months (range 1-159). Relapse or disease progression after PBSCT was a frequent cause of death, but no therapy-related mortality associated with PBSCT was observed. The 5-year overall survival and progression-free survival were 70.6% (95% confidence interval [CI], 54.0-82.1) and 57.0% (95% CI, 39.5-71.2), respectively. Chronic renal impairment, therapy-related myelodysplastic syndrome and prostate cancer were the major late complications. The CEM regimen is a tolerable, effective conditioning regimen for autologous PBSCT for DLBCL, with no therapy-related mortality observed.
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Transplantation Conditioning
Cyclophosphamide
medicine.medical_treatment
Follicular lymphoma
Kaplan-Meier Estimate
Ranimustine
Transplantation, Autologous
Disease-Free Survival
Nitrosourea Compounds
Young Adult
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Etoposide
Retrospective Studies
Peripheral Blood Stem Cell Transplantation
Chemotherapy
Dose-Response Relationship, Drug
business.industry
Hematology
Middle Aged
medicine.disease
Combined Modality Therapy
Lymphoma
Surgery
Regimen
Treatment Outcome
Disease Progression
Female
Lymphoma, Large B-Cell, Diffuse
Neoplasm Recurrence, Local
business
Diffuse large B-cell lymphoma
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 55
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....0efa81922e7c8e947895af848c1e3cab